The cancer vaccine revolution: Where does Bangladesh stand?

Cancer treatment has traditionally relied on surgery, chemotherapy and radiation. However, a new approach is gaining traction: personalized mRNA cancer vaccines designed to teach the immune system to recognize and combat individual patients' tumors. These vaccines, inspired by the success of mRNA technology during the Covid-19 pandemic, are currently in advanced stages of testing for various cancers, including melanoma.

The process begins with a sample of a patient's tumor and a blood sample. Scientists then compare the tumor cells with healthy cells to pinpoint unique features distinguishing the cancer. Using this information, a custom set of instructions is created to help the immune system identify the cancer. Once injected, these instructions prompt the body to produce harmless copies of specific cancer markers, which act as "wanted posters" to help the immune system locate and attack cancer cells while minimizing damage to healthy tissue.

For Bangladesh, the potential of personalized cancer vaccines is accompanied by significant challenges. The country lacks the necessary research facilities, diagnostic laboratories, testing capabilities, and skilled researchers to make these highly tailored treatments widely accessible. International collaborations and stronger healthcare infrastructure will be crucial for Bangladesh to participate in this new era of cancer care.

Dr. Sabiruddin Mirza, a senior research fellow at Harvard University, is working on improving how vaccine instructions reach the right cells. He envisions a future where collaboration between Bangladeshi institutions and universities, hospitals, and research centers in the United States could lead to training, knowledge exchange, and locally driven innovation.

Cost remains a major obstacle, as personalized vaccines demand sophisticated testing and manufacturing processes, raising questions about affordability and accessibility. Additionally, challenges related to delivery, large-scale production, and regulatory approval must be addressed. Despite these hurdles, the potential impact is significant.

Cancer treatment may gradually shift from broad therapies targeting tumors to individualized treatments that teach each patient's immune system to recognize their unique cancer. For Bangladesh, the opportunity lies not in merely importing tomorrow's medicine, but in building the scientific capacity to contribute to and benefit from this transformative approach.